Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Kovack Advisors Inc.

Kovack Advisors Inc. raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 347.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,971 shares of the specialty pharmaceutical company’s stock after acquiring an additional 23,267 shares during the quarter. Kovack Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $3,686,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. increased its stake in Jazz Pharmaceuticals by 2.5% in the third quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company’s stock valued at $528,000 after purchasing an additional 100 shares during the last quarter. Waterfront Wealth Inc. increased its stake in Jazz Pharmaceuticals by 1.2% in the fourth quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock valued at $1,062,000 after purchasing an additional 103 shares during the last quarter. Prime Capital Investment Advisors LLC increased its stake in Jazz Pharmaceuticals by 4.3% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after purchasing an additional 108 shares during the last quarter. Johnson Investment Counsel Inc. increased its stake in Jazz Pharmaceuticals by 0.8% in the third quarter. Johnson Investment Counsel Inc. now owns 13,096 shares of the specialty pharmaceutical company’s stock valued at $1,695,000 after purchasing an additional 110 shares during the last quarter. Finally, Fifth Third Bancorp increased its stake in Jazz Pharmaceuticals by 2.2% in the third quarter. Fifth Third Bancorp now owns 5,339 shares of the specialty pharmaceutical company’s stock valued at $691,000 after purchasing an additional 114 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 1.9 %

Shares of JAZZ stock traded up $2.03 during trading hours on Friday, reaching $109.46. The company had a trading volume of 480,574 shares, compared to its average volume of 604,480. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24. Jazz Pharmaceuticals plc has a twelve month low of $106.61 and a twelve month high of $146.70. The company has a market capitalization of $6.90 billion, a P/E ratio of 17.89, a price-to-earnings-growth ratio of 1.50 and a beta of 0.59. The stock’s fifty day simple moving average is $118.25 and its 200 day simple moving average is $121.81.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. As a group, sell-side analysts expect that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 1st. The shares were purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

JAZZ has been the subject of several analyst reports. Stifel Nicolaus upped their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. UBS Group dropped their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research note on Friday, March 1st. JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Finally, Piper Sandler upped their price target on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $195.08.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.